Immunotherapy in Myeloma A Theme Issue in Honor of Prof. Dr. Gösta Gahrton
Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_78777 | ||
| 005 | 20220224 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220224s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-2907-3 | ||
| 020 | |a 9783036529073 | ||
| 020 | |a 9783036529066 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2907-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Kröger, Nicolaus |4 edt | |
| 700 | 1 | |a Garderet, Laurent |4 edt | |
| 700 | 1 | |a Kröger, Nicolaus |4 oth | |
| 700 | 1 | |a Garderet, Laurent |4 oth | |
| 245 | 1 | 0 | |a Immunotherapy in Myeloma |b A Theme Issue in Honor of Prof. Dr. Gösta Gahrton |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (124 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a multiple myeloma | ||
| 653 | |a immunotherapy | ||
| 653 | |a daratumumab | ||
| 653 | |a BCMA | ||
| 653 | |a bi-specific T cell engagers | ||
| 653 | |a chimeric antigen receptor | ||
| 653 | |a relapse | ||
| 653 | |a cytokine-release syndrome | ||
| 653 | |a allogeneic transplantation | ||
| 653 | |a myeloablative | ||
| 653 | |a non-myeloablative | ||
| 653 | |a new drugs | ||
| 653 | |a CAR T | ||
| 653 | |a antibodies | ||
| 653 | |a monoclonal | ||
| 653 | |a bispecific | ||
| 653 | |a immunoconjugates | ||
| 653 | |a antibody-drug conjugates | ||
| 653 | |a myeloma | ||
| 653 | |a NK cells | ||
| 653 | |a immunomodulation | ||
| 653 | |a cell therapy | ||
| 653 | |a graft-versus-myeloma | ||
| 653 | |a donor lymphocyte infusion | ||
| 653 | |a allogeneic stem cell transplantation | ||
| 653 | |a prophylaxis | ||
| 653 | |a salvage | ||
| 653 | |a CAR T-cells | ||
| 653 | |a target antigen | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4871 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78777 |7 0 |z DOAB: description of the publication |